PUBLIC COMPANY
save$CNTACentessa Pharmaceuticals plc
$CNTA40.500.00%Altrincham, Cheshire, GBupdated 3mo ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Lilly’s early-stage M&A quest finds $1.5B deal for Calytrix’s blood cancer workEli Lilly's business development team has inked 14 buyouts this year so far, with Calytrix Bio tucking into the pharma’s oncology pipeline.biospace · 20h ago
- Lilly secures another myelofibrosis option via $1.5B deal for JPM-founded CalytrixEli Lilly has added another myelofibrosis prospect to its pipeline courtesy of a $1.5 billion deal for Massachusetts biotech Calytrix Bio.fiercebiotech · 1d ago
- Eli Lilly scraps phase 2 Alzheimer's program after drug falls short of expectationsEli Lilly has dropped its phase 2 Alzheimer's disease program for mevidalen, marking another setback for the experimental drug as the Big Pharma expands its neuroscience pipeline through multibilli…fiercebiotech · 19d ago
- M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buyAfter a frantic second quarter, M&A steadied with just under $30 billion across 22 total transactions, according to a BioSpace analysis.biospace · 1mo ago
- Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCareInnoCare Pharma is the latest addition to Eli Lilly’s dealmaking spree, which includes some of the biggest acquisitions this year: up to $7 billion for Kelonia Therapeutics in April and up to $7.8…biospace · 1mo ago
- Chutes & Ladders—Legend poaches Novartis vet to boost commercial potentialAfter former Legend Biotech CEO Ying Huang, Ph.D., left the company suddenly in July, Legend has found its permanent CEO, poaching Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its nex…fiercebiotech · 2mo ago
- Deal-hungry Lilly strikes up to $2.9B immuno play for MeridaWith the acquisition of Merida Biosciences, Eli Lilly is gaining a precision degradation platform for therapies that selectively target and destroy pathologic antibodies for allergic and autoimmune…biospace · 2mo ago
- Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodiesEli Lilly has struck a deal to acquire Merida Biosciences for up to $2.875 billion, establishing a beachhead in efforts to treat disease through the selective degradation of pathogenic autoantibodies.fiercebiotech · 2mo ago
- ‘A neuroscience revolution’: The GLP-like race to keep us awake and make billions doing itAs the hype around the vast medical potential of GLP-1 drugs continues unabated, another peptide is starting to make its own mark.fiercebiotech · 2mo ago
- Takeda leads wave of orexin drugs with potential to upend narcolepsy marketThe FDA’s August approval of Takeda’s Orzeyful for treating the full set of narcolepsy symptoms initiated a new era in the sleep market.biospace · 3mo ago
Data sources
last refreshed 52m ago
Found something off?
comments(0)
5-min edit window · permanent after that